The Influence of Adjuvants on Antigenic Properties of Peptide Constructs Composed of Hepatitis C Virusenvelope Protein E2 Fragments

Article Sidebar

pdf (Русский)
Published: Feb 10, 2025
DOI: https://doi.org/10.18097/BMCRM00227
Keywords:
peptide vaccines; hepatitis C virus; envelope proteins; peptide synthesis; adjuvants; Immunomax

Main Article Content

E.A. Egorova
Institute of Biomedical Chemistry, 10 Pogodinskaya str., Moscow, 119121 Russia; Sirius University of Science and Technology, 1 Olympic Ave., Sirius Federal Territory, Russia
T.M. Melnikova
N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 47 Leninsky Ave., Moscow, Russia
M.V. Melnikova
Institute of Biomedical Chemistry, 10 Pogodinskaya str., Moscow, 119121 Russia; Research Zakusov Institute of Pharmacology, 8 Baltiyskaya str., Moscow, Russia
M.G. Zavyalova
Institute of Biomedical Chemistry, 10 Pogodinskaya str., Moscow, 119121 Russia
L.V. Kostryukova
Institute of Biomedical Chemistry, 10 Pogodinskaya str., Moscow, 119121 Russia
O.V. Chibiskova
Institute of Biomedical Chemistry, 10 Pogodinskaya str., Moscow, 119121 Russia
R.I. Ataullakhanov
National Research Center – Institute of Immunology Federal Medical-Biological Agency of Russia, 24 Kashirskoe Rd., Moscow, Russia
E.F. Kolesanova
Institute of Biomedical Chemistry, 10 Pogodinskaya str., Moscow, 119121 Russia

Abstract

Effectiveness of the immune response in the form of the production of specific antibodies against immunogenic peptide constructs composed of conservative fragments of the hepatitis C virus envelope protein E2 depended on the adjuvants and carriers used in their preparations. The most effective formation of specific antibodies was observed in response to the injection of peptide constructs containing B- and T-epitopes of the E2 protein conjugated with a carrier with adjuvant properties, Immunomax. Antibodies obtained in response to immunization with conjugates of peptide constructs with Immunomax bound both hepatitis C virus envelope protein E2 and the heterodimer of envelope proteins E1E2.

Article Details

How to Cite
Egorova, E., Melnikova, T., Melnikova, M., Zavyalova, M., Kostryukova, L., Chibiskova, O., Ataullakhanov, R., & Kolesanova, E. (2025). The Influence of Adjuvants on Antigenic Properties of Peptide Constructs Composed of Hepatitis C Virusenvelope Protein E2 Fragments. Biomedical Chemistry: Research and Methods, 8(1), e00227. https://doi.org/10.18097/BMCRM00227
Issue
Vol. 8 No. 1 (2025): Online first
Section
EXPERIMENTAL RESEARCH

References

  1. Klade, C.S., Wedemeyer, H., Berg, T., Hinrichsen, H., Cholewinska, G.,Zeuzem, S., Blum, H., Buschle, M., Jelovcan, S., Buerger, V., Tauber, E.,Frisch, J., Manns, M.P.(2008) Therapeutic Vaccination of Chronic HepatitisC Nonresponder Patients with the Peptide Vaccine IC41. Gastroenterology,134(5), 1385-1395. DOI
  2. Firbas, C., Boehm, T., Buerger, V., Schuller, E., Sabarth, N., Jilma, B.,Klade, C.S. (2010) Immunogenicity and safety of different injection routes andschedules of IC41, a Hepatitis C virus (HCV) peptide vaccine. Vaccine, 28(12),2397-407. DOI
  3. Ryzhikov, A.B., Ryzhikov, E.A., Bogryantseva, M.P., Danilenko, E.D.,Imatdinov, I.R., Nechaeva, E.A., Pyankov, O.V. et all. (2021) Immunogenicityand Protectivity of the Peptide Vaccine against SARS-CoV-2. Annals of theRussian Academy of Medical Sciences, 76(1), 5–19. DOI
  4. Barchuk, A., Bulina, A., Cherkashin, M., Berezina, N., Rakova,, T.,Kuplevatskaya, D., Skougarevskiy, D., Okhotin, A. (2022) Gam-COVID-Vac,EpiVacCorona, and CoviVac effectiveness against lung injury during Delta andOmicron variant surges in St. Petersburg, Russia: a test-negative case-controlstudy. Respiratory Research, 23(1), 276. DOI
  5. Matveeva, O, Ershov, A. (2022) Retrospective Cohort Study of theEffectiveness of the Sputnik V and EpiVacCorona Vaccines against the SARSCoV-2 Delta Variant in Moscow (June-July 2021). Vaccines (Basel), 10(7), 984. DOI
  6. Moysa, A.A., Kolesanova, E.F. (2011) Synthetic peptide vaccines.Biomeditsinskaya Khimiya, 57 (1), 14-30. DOI
  7. Chandpa, H.H., Panda, A.K., Meena, C.L., Meena, J. (2023) Beyond thepolysaccharide and glycoconjugate vaccines for Streptococcus pneumoniae:Does protein/peptide nanovaccines hold promises? Vaccine, 41(50), 7515-7524. DOI
  8. Koirala, P., Shalash, A.O., Chen, S.R., Faruck, M.O., Wang, J., Hussein,W.M., Khalil, Z.G., Capon, R.J., Monteiro, M.J., Toth, I., Skwarczynski, M.(2024) Polymeric Nanoparticles as Oral and Intranasal Peptide Vaccine DeliverySystems: The Role of Shape and Conjugation. Vaccines (Basel), 12(2), 198. DOI
  9. Román-Cruz, V.C., Miller, S.M., Schoener, R.A., Lukasiewicz, C., Schmidt,A.K., DeBuysscher, B.L., Burkhart, D., Seco, P.R., Evans, J.T. (2024)Adjuvanted Vaccine Induces Functional Antibodies against Pseudomonasaeruginosa Filamentous Bacteriophages. Vaccines (Basel), 12(2), 115. DOI
  10. Huang, Z., Gong, H., Sun, Q., Yang, J., Yan, X.. (2024) Research progress onemulsion vaccine adjuvants. Heliyon. 10(3), e24662. DOI
  11. . Aleshina, E.Y., Pyndyk, N.V., Moisa, A.A., Sanzhakov, M.A., Kharybin,O.N., Nikolaev, E.N., Kolesanova, E.F. (2008) Synthesis of b-amyloid fragment5 RHDSGY10 and its isomers with the use of new solid-phase peptide synthesisschedule. Biomeditsinskaya Khimiya, 54(2). 184-191.
  12. Kolesanova, E.F., Farafonova, T.E., Aleshina, E.Y., Pyndyk, N.V., Veremieva,M.V., Novosylna, A.V., Kovalenko, M.I., Shalak, V.F, Negrutskii, B.S. (2014)Preparation of monospecific antibodies against isoform 2 of translationelongation factor 1A (eEF1A2). Biomeditsinskaya Khimiya, 60(1), 51-62. DOI
  13. Belyavtsev, A.N., Shastina, N.S., Kupriyanov, V.V., Nikolaeva, L.I.,Mel’nikova, M.V., Kolesanova, E.F., Shimchishina, M.Y., Kapustin, I.V. (2022)The influence of lipid components on the immunogenicity of synthetic fragmentof the virus hepatitis C antigen NS4A. Bioorganicheskaya Khimiya, 48, 453-460 DOI
  14. Hou, S.J., Saksena, R., Kovác, P. (2008) Preparation of glycoconjugates bydialkyl squarate chemistry revisited. Carbohydrate Research, 343(2), 196-210. DOI
  15. Kuzmina, T.I., Olenina, L.V., Sanzhakov, M.A., Farafonova, T.E.,Abramihina, T.V., Dubuisson, J., Sobolev, B.N., Kolesanova, E.F. (2009)Antigenicity and B-epitope mapping of hepatitis C virus envelope protein E2.Biomeditsinskaya Khimiya, 55(1), 32-40.
  16. Olenina, L.V., Nikolaeva, L.I., Sobolev, B.N., Blokhina, N.P., Archakov, A.I.,Kolesanova, E.F. (2002) Mapping and characterization of B cell linear epitopesin the conservative regions of hepatitis C virus envelope glycoproteins. Journalof Viral Hepatitis, 9(3), 174-182. DOI
  17. Schuler, M.M., Nastke, M.-D., Stevanović, S.. (2007) SYFPEITHI: databasefor searching and T-cell epitope prediction. Methods in Molecular Biology, 409,75-93. DOI
  18. Vita, R.R., Overton, J.A., Greenbaum, J.A., Ponomarenko, J , Clark, J.D.,Cantrel, J.R., Wheeler, D.K., Gabbard, J.L., Hix, D., Sette, A., Peters, B. (2015)The immune epitope database (IEDB) 3.0. Nucleic Acids Reseach, 43(Databaseissue), D405–D412. DOI
  19. Kolesanova, E.F., Sobolev, B.N., Moisa, A.A., Egorova, E.A., Archako,v A.I.(2015) The way to the peptide vaccine against hepatitis C. BiomeditsinskayaKhimiya, 61(2), 254-264]. DOI
  20. Sobolev, B N., Poroikov, V.V., Olenina, L.V., Kolesanova, E.F., Archakov, A.I.(2000) Comparative analysis of amino acid sequences from envelope proteinsisolated from different hepatitis C virus variants: possible role of conservativeand variable. . Journal of Viral Hepatitis, 7(5), 368-374. DOI
  21. Olenina, L.V., Kuzmina, T.I., Sobolev, B.N., Kuraeva, T.E., Kolesanova, E.F.,Archakov A.I. (2005) Identification of glycosaminoglycan-binding sites withinhepatitis C virus envelope glycoprotein E2. Journal of Viral Hepatitis, 12(6),584-593. DOI
  22. Zeisel, M.B., Felmlee, D.J., Baumert, T.F. (2013) Hepatitis C virus entry.Curr. Topics Microbiol.Immunol., 369, 87-112. DOI
  23. Farafonova, T.E., Olenina, L.V., Kolesanova ,E.F. Putative hepatitis C viruscell receptors. Biomeditsinskaya Khimiya, 54(2), 154-166.1.
  24. Semmo, N., Klenerman, P. (2007) CD4+ T cell responses in hepatitis C virusinfection. World J. Gastroenterol., 13(36), 4831-4838. DOI
  25. Margaroni, M., Tsanaktsidou, E., Agallou, M., Kiparissides, C., Kammona,O., Karagouni, E. (2024) Development of a novel squalene/α-tocopherol-basedself-emulsified nanoemulsion incorporating Leishmania peptides for inductionof antigen-specific immune responses. International Journal of Pharmacology,649,123621. DOI
  26. Fox, C.B., Baldwin, S.L., Duthie, M.S., Reed, S.G., Vedvick, T.S.. (2012)Immunomodulatory and physical effects of phospholipid composition invaccine adjuvant emulsions. AAPS PharmSciTech, 13(2), 498-506. DOI
  27. Ataullakhanov, R.I., Pichugin, A.V., Mel’nikova, T.M., Khaitov, R.M.(2015) A method for producing a substance with antimicrobial, antiviral andimmunostimulating activity, in particular, against dendritic cells, a substanceobtained by this method, and a pharmaceutical composition based on it. RussianState Patent Agency Certificate, No.2 563 818 of 21.11.2013.
  28. Nikonova, A.A., Pichugin, A.V., Chulkina, M.M., Lebedeva, E.S., Gaisina,A.R., Shilovskiy, I.P., Ataullakhanov, R.I., Khaitov, M.R., Khaitov, R.M.(2018) The TLR4 agonist Immunomax affects the phenotype of mouse lungmacrophages during respiratory syncytial virus infection. Acta Naturae, 10(4), 95-99.
  29. Masalova, O.V., Lesnova, E.I., Pichugin, A.V., Mel’nikova, T.M., Ulanov,T.I., Burkov, A.N., Ataullakhanov, R.I., Kushch ,A.A. (2008) Issledovanieimmunogennosti kovalentnyh konyugatov nestrukturnyh belkov virusa gepatitaC s Immunomaksom. Immunologiya, 29, 338-345.
  30. Hernandez, A., Patil, N.K., Stother, C.L., Luan, L., McBride, M.A., Owen,A.M., Burelbach, K.R., Williams, D.L., Sherwood, E.R., Bohannon, J.K. (2019)Immunobiology and application of toll-like receptor 4 agonists to augment hostresistance to infection. Pharmacological Research, 150, 104502. DOI